203. 22q11.2 deletion syndrome Clinical trials / Disease details
Clinical trials : 5 / Drugs : 7 - (DrugBank : 1) / Drug target genes : 14 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-002011-61-NL (EUCTR) | 13/08/2021 | 21/06/2021 | Riluzole as treatment for psychotic and cognitive symptoms in 22q11.2 deletion syndrome | The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome - Riluzole in 22q11.2DS | 22q11.2 deletion syndrome;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Trade Name: Rilutek Product Name: Riluzole Product Code: EMEA/H/C/000109 | Academisch ziekenhuis Maastricht | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 45 | Phase 3 | Netherlands | ||
| 2 | NCT05149898 (ClinicalTrials.gov) | March 3, 2020 | 5/10/2021 | Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome | Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome | 22Q Deletion Syndrome | Drug: ZYN002 | Zynerba Pharmaceuticals, Inc. | NULL | Recruiting | 4 Years | 17 Years | All | 20 | Phase 1/Phase 2 | United States;Australia |
| 3 | NCT04639960 (ClinicalTrials.gov) | September 29, 2017 | 3/11/2020 | Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome | Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome | 22q11.2 Deletion Syndrome | Drug: Risperdal;Drug: Placebo | University of Geneva, Switzerland | NULL | Recruiting | 11 Years | 25 Years | All | 30 | N/A | Switzerland |
| 4 | NCT02895906 (ClinicalTrials.gov) | November 28, 2016 | 29/8/2016 | Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions | A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD) | 22q11.2 Deletion Syndrome | Drug: NFC-1 | Aevi Genomic Medicine | NULL | Completed | 12 Years | 17 Years | All | 2 | Phase 1 | United States |
| 5 | NCT04647500 (ClinicalTrials.gov) | August 26, 2016 | 3/11/2020 | Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome | Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome | 22q11.2 Deletion Syndrome | Drug: Concerta | University of Geneva, Switzerland | NULL | Recruiting | 8 Years | 25 Years | All | 30 | N/A | Switzerland |